Purchase this article with an account.
AE Albritton, JA Stewart, JN Leech, AL Jackson, WC Stewart; Conjunctival Hyperemia With Latanoprost, Travoprost and Bimatoprost . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4112.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate conjunctival hyperemia between latanoprost 0.005%, bimatoprost 0.03% and travoprost 0.004% in healthy individuals. Methods: We evaluated conjunctival hyperemia, by a standard photographic measure grade (0-4), at the slit lamp in healthy subjects after dosing for five days with either latanoprost, bimatoprost or travoprost. Conjunctival hyperemia was evaluated at 24 hour trough (Hour 0) and at Hour 1 after dosing. Results: Twenty-eight subjects completed this study. From baseline slit lamp mean grade was 0.77 0.68, at 24 hours after dosing the grade for latanoprost was 1.36 0.87, bimatoprost 1.89 0.83, and travoprost 1.61 0.83. One hour after dosing the grade was 1.18 0.82 for latanoprost, 1.43 0.74 for bimatoprost and 1.64 0.87 for travoprost. Several comparisons were noted to be significant between groups by slit lamp biomicroscopy: first, at Hour 0 latanoprost had significantly less hyperemia than bimatoprost; second, at Hour 0 latanoprost showed significantly less change than bimatoprost compared to the study baseline (Visit 2); third, at Hour 1 latanoprost had significantly less hyperemia than travoprost; fourth, at Hour 1 latanoprost demonstrated significantly less change in hyperemia than travoprost from baseline (Visit 2); fifth, at Hour 1 latanoprost had less change in hyperemia than bimatoprost or travoprost between the study and the non-study eye (P = 0.03); and last, at Hour 1 latanoprost showed significantly less change than bimatoprost and travoprost compared to Hour 0 (P = 0.04). Subjects complained less about other people noticing their red eye with latanoprost than bimatoprost or travoprost (P = 0.048). No serious adverse events were noted. Conclusion: This study suggests that latanoprost may cause less short-term conjunctival hyperemia on average than travoprost or bimatoprost in healthy subjects.
This PDF is available to Subscribers Only